A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Public ClinicalTrials.gov record NCT07415031. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)
Study identification
- NCT ID
- NCT07415031
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Enrollment
- 170 participants
Conditions and interventions
Conditions
Interventions
- Adagrasib Drug
- Cetuximab Drug
- Docetaxel Drug
- Fluorouracil Drug
- Irinotecan Drug
- Leucovorin Drug
- Oxaliplatin Drug
- Pembrolizumab Drug
- Pemetrexed Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 15, 2026
- Primary completion
- Feb 15, 2028
- Completion
- Feb 15, 2028
- Last update posted
- Apr 7, 2026
2026 – 2028
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0005 | Phoenix | Arizona | 85054 | — |
| Local Institution - 0016 | Bellflower | California | 90706 | — |
| Local Institution - 0003 | Newark | Delaware | 19713 | — |
| Local Institution - 0001 | St. Petersburg | Florida | 33701 | — |
| Local Institution - 0064 | Chicago | Illinois | 60637 | — |
| Local Institution - 0017 | Rochester | Minnesota | 55905 | — |
| Local Institution - 0073 | Saint Paul | Minnesota | 55101 | — |
| Local Institution - 0036 | Omaha | Nebraska | 68114 | — |
| Local Institution - 0028 | East Syracuse | New York | 13057 | — |
| Local Institution - 0004 | Eugene | Oregon | 97401 | — |
| Local Institution - 0023 | Germantown | Tennessee | 38138 | — |
| Local Institution - 0002 | Grapevine | Texas | 76051 | — |
| Local Institution - 0013 | Bellingham | Washington | 98225 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07415031, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 7, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07415031 live on ClinicalTrials.gov.